MESO stock forecast, quote, news & analysis
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions... Show more
Why Mesoblast Limited (MESO) Is Down -15% in the Last 30 Days
Key Takeaways
- MESO stock declined approximately -15% over the past 30 days amid profit-taking following strong Ryoncil sales reports and broader biotech sector volatility.
- Over the past quarter, the stock is down around -30%, reflecting a pullback from January highs despite positive revenue growth from its lead product Ryoncil.
- Key drivers include robust Ryoncil net sales of $30.3M in the March quarter, H1 FY2026 earnings beat with $51.3M revenue, but tempered by ongoing losses and pipeline execution risks.
- Market sentiment shifted with post-earnings selloff and anticipation of upcoming R&D Day on April 8.
- Biotech sector trends and high short interest contributed to volatile price movement.
Mesoblast Limited (MESO) Company Overview and Market Position
Mesoblast Limited (MESO) is an Australia-based biopharmaceutical company specializing in allogeneic cellular medicines derived from mesenchymal lineage cells. Its core business model focuses on developing off-the-shelf therapies for severe inflammatory conditions, cardiovascular diseases, and back pain. Key products include Ryoncil, approved for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD), and pipeline candidates like Revascor for heart failure and MPC-06-ID for chronic low back pain.
In the competitive regenerative medicine industry, Mesoblast holds a strong position with FDA-approved Ryoncil and partnerships such as Tasly Pharmaceutical and JCR Pharmaceuticals. Its fundamentals, including growing Ryoncil revenues and a fortified balance sheet with $130M cash plus a $125M credit facility, underpin recent stock behavior despite clinical and commercialization risks typical in biotech.
Mesoblast Limited (MESO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MESO stock fell approximately -15%, from around $15.85 (early March close) to $13.45 (latest available). The movement was volatile and trend-driven downward, with sharp drops on high volume days amid sector pressures.
For the past quarter, the stock declined about -30%, retreating from $19.26 (early January) to the current level. Performance was range-bound initially before accelerating lower post-earnings, reflecting biotech volatility rather than steady decline.
What Drove MESO Stock Price in the Last 30 Days
The 30-day downturn was primarily driven by profit-taking after strong March quarter Ryoncil net sales of $30.3M, signaling a successful first-year launch but prompting selloffs as investors locked in gains. High survival rates in expanded access programs for SR-aGVHD reinforced efficacy but did little to stem the decline amid broader biotech weakness.
Recent announcements, including an upcoming R&D Day on April 8 and the appointment of Dr. Teresa Montagut as Clinical Development head, provided mild support but were overshadowed by market sentiment shifts. Analyst notes on revenue guidance also led to a 7.1% drop, as focus turned to profitability challenges despite revenue beats.
What Drove MESO Stock Performance Over the Last Quarter
The quarterly -30% drop followed a peak near $21.50 in early January, driven by anticipation of H1 FY2026 results released late February. Revenue surged to $51.3M (beating estimates), powered by $49M from Ryoncil with 93% gross margins, narrowing losses and validating the commercial launch.
However, sustained downward pressure came from biotech sector headwinds, including interest rate sensitivity and investor caution on cash burn. Positive real-world data showing 84% survival rates and pipeline progress like adult SR-aGVHD trials offered counterbalance, but institutional profit-taking dominated. Macro factors like inflation concerns impacted high-growth biotechs, amplifying the pullback.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots out of hundreds that trade thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, win rates, and relevance to current market trends, employing diverse strategies such as trend-following, mean reversion, or momentum trading over short-term (intraday) to long-term (weekly/monthly) timeframes. Users can explore detailed stats like average return, Sharpe ratio (a measure of risk-adjusted performance), and trade history to identify bots aligning with their risk tolerance and goals. While past performance does not guarantee future results, this section highlights innovative tools for automated trading. Check out the Trending AI Robots page to discover bots potentially suited for your portfolio.
MESO Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the R&D Day on April 8 for pipeline updates on Revascor and chronic back pain trials. Upcoming H2 FY2026 earnings will provide further Ryoncil sales traction and cash runway insights. Progress in adult SR-aGVHD pivotal trial could expand the addressable market significantly.
Industry trends in cellular therapies, macroeconomic factors like interest rates affecting biotech funding, and strategic partnerships remain key. Risks include regulatory hurdles, competition from established therapies, and dilution from capital raises, alongside catalysts like new data readouts or label expansions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
MESO's RSI Indicator climbs out of oversold territory
The RSI Indicator for MESO moved out of oversold territory on March 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MESO just turned positive on March 25, 2026. Looking at past instances where MESO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MESO as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for MESO moved below the 200-day moving average on April 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MESO broke above its upper Bollinger Band on April 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MESO entered a downward trend on March 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MESO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.263) is normal, around the industry mean (26.133). P/E Ratio (0.000) is within average values for comparable stocks, (45.240). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (28.571) is also within normal values, averaging (316.299).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of biological products
Industry Biotechnology